Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

206 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Immunotherapy in multiple myeloma: when, where, and for who?
Verkleij CPM, Korst CLBM, van de Donk NWCJ. Verkleij CPM, et al. Among authors: van de donk nwcj. Curr Opin Oncol. 2020 Nov;32(6):664-671. doi: 10.1097/CCO.0000000000000677. Curr Opin Oncol. 2020. PMID: 32852308 Review.
CD38 antibodies in multiple myeloma: back to the future.
van de Donk NWCJ, Richardson PG, Malavasi F. van de Donk NWCJ, et al. Blood. 2018 Jan 4;131(1):13-29. doi: 10.1182/blood-2017-06-740944. Epub 2017 Nov 8. Blood. 2018. PMID: 29118010 Free article. Review.
Pomalidomide Plus Low-Dose Dexamethasone in Patients With Relapsed/Refractory Multiple Myeloma and Renal Impairment: Results From a Phase II Trial.
Dimopoulos M, Weisel K, van de Donk NWCJ, Ramasamy K, Gamberi B, Streetly M, Offidani M, Bridoux F, de la Rubia J, Mateos MV, Ardizzoia A, Kueenburg E, Collins S, Di Micco A, Rosettani B, Li Y, Bacon P, Sonneveld P. Dimopoulos M, et al. Among authors: van de donk nwcj, de la rubia j. J Clin Oncol. 2018 Jul 10;36(20):2035-2043. doi: 10.1200/JCO.2017.76.1742. Epub 2018 Feb 2. J Clin Oncol. 2018. PMID: 29394124 Clinical Trial.
CD38-targeting antibodies in multiple myeloma: mechanisms of action and clinical experience.
Frerichs KA, Nagy NA, Lindenbergh PL, Bosman P, Marin Soto J, Broekmans M, Groen RWJ, Themeli M, Nieuwenhuis L, Stege C, Nijhof IS, Mutis T, Zweegman S, Lokhorst HM, van de Donk NWCJ. Frerichs KA, et al. Among authors: van de donk nwcj. Expert Rev Clin Immunol. 2018 Mar;14(3):197-206. doi: 10.1080/1744666X.2018.1443809. Epub 2018 Feb 28. Expert Rev Clin Immunol. 2018. PMID: 29465271 Review.
Immunotherapy in myeloma: how far have we come?
Franssen LE, Mutis T, Lokhorst HM, van de Donk NWCJ. Franssen LE, et al. Among authors: van de donk nwcj. Ther Adv Hematol. 2019 Jan 18;10:2040620718822660. doi: 10.1177/2040620718822660. eCollection 2019. Ther Adv Hematol. 2019. PMID: 30719268 Free PMC article. Review.
Subcutaneous delivery of daratumumab in relapsed or refractory multiple myeloma.
Usmani SZ, Nahi H, Mateos MV, van de Donk NWCJ, Chari A, Kaufman JL, Moreau P, Oriol A, Plesner T, Benboubker L, Hellemans P, Masterson T, Clemens PL, Luo M, Liu K, San-Miguel J. Usmani SZ, et al. Among authors: van de donk nwcj. Blood. 2019 Aug 22;134(8):668-677. doi: 10.1182/blood.2019000667. Epub 2019 Jul 3. Blood. 2019. PMID: 31270103 Free PMC article. Clinical Trial.
Preclinical Activity of JNJ-7957, a Novel BCMA×CD3 Bispecific Antibody for the Treatment of Multiple Myeloma, Is Potentiated by Daratumumab.
Frerichs KA, Broekmans MEC, Marin Soto JA, van Kessel B, Heymans MW, Holthof LC, Verkleij CPM, Boominathan R, Vaidya B, Sendecki J, Axel A, Gaudet F, Pillarisetti K, Zweegman S, Adams HC 3rd, Mutis T, van de Donk NWCJ. Frerichs KA, et al. Among authors: van de donk nwcj, van kessel b. Clin Cancer Res. 2020 May 1;26(9):2203-2215. doi: 10.1158/1078-0432.CCR-19-2299. Epub 2020 Jan 22. Clin Cancer Res. 2020. PMID: 31969333
206 results